{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:58:21Z","timestamp":1792623501127,"version":"4.5.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma is the second most frequent hematological disease. The introduction of melphalan as high-dose therapy followed by autologous hematopoietic cell transplantation (HDT\/ASCT) for young patients and the availability of novel agents for young and elderly patients with multiple myeloma have dramatically changed the perspective of treatment. However, further research is necessary if we want definitively to cure the disease. Treatment goals for transplant-eligible and non\u2013transplant-eligible patients should be to prolong survival by achieving the best possible response while ensuring quality of life. For young patients, HDT-ASCT is a standard of care for treatment, and its efficacy has been enhanced and challenged by the new drugs. For elderly patients, treatment options were once limited to alkylators, but new upfront treatment combinations based on novel agents (proteasome inhibitors and immunomodulatory drugs) combined or not with alkylators have significantly improved outcomes. Extended treatment of young and elderly patients improves the quality and duration of clinical responses; however, the optimal scheme, appropriate doses, and duration of long-term therapy have not yet been fully determined. This review summarizes progress in the treatment of patients with newly diagnosed multiple myeloma, addressing critical questions such as the optimal induction, early vs late ASCT, consolidation and\/or maintenance for young patients, and how we can choose the best treatment option for non\u2013transplant-eligible patients.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.498","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"498-507","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["Management of multiple myeloma in the newly diagnosed patient"],"prefix":"10.1182","volume":"2017","author":[{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"Hospital Universitario de Salamanca-Instituto Biosanitario de Salamanca, Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111703162915800_B1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111703162915800_B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"issue":"20","key":"2019111703162915800_B3","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703162915800_B4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2019111703162915800_B5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17474086.2014.871200","article-title":"Initial treatment of transplant-eligible patients in multiple myeloma","volume":"7","author":"Rosi\u00f1ol","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"9758","key":"2019111703162915800_B6","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"2019111703162915800_B7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111703162915800_B8","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111703162915800_B9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111703162915800_B10","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"2019111703162915800_B11","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111703162915800_B12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111703162915800_B13","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111703162915800_B14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703162915800_B15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/blood.V124.21.197.197","article-title":"Superior efficacy of VTD over VCD as induction therapy for autotransplantation-eligible, newly diagnosed, myeloma patients","volume":"124","author":"Cavo","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111703162915800_B16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"2019111703162915800_B17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V128.22.1142.1142","article-title":"Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du My\u00e9Lome (IFM) Krd phase II study","volume":"128","author":"Roussel","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V128.22.674.674","article-title":"Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du My\u00e9Lome (IFM)","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111703162915800_B20","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V122.21.3179.3179","article-title":"A phase I\/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort","volume":"122","author":"Reeder","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111703162915800_B21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703162915800_B22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111703162915800_B23","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"2019111703162915800_B24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V128.22.673.673","article-title":"Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","article-title":"Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B26","author":"Cavo","year":"2012"},{"key":"2019111703162915800_B27","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem Autohct with Len maintenance (TAM) and Autohct with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V128.22.242.242","article-title":"Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111703162915800_B29","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111703162915800_B30","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111703162915800_B31","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2016.34.15_suppl.8001","article-title":"Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS) [abstract]","volume":"34","author":"Attal","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111703162915800_B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V126.23.27.27","article-title":"Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65\/GMMG-HD4 Trial","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111703162915800_B33","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer J"},{"key":"2019111703162915800_B34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages: results of the phase III Myeloma XI study","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial [published online ahead of print 14 February 2017]","author":"Rosi\u00f1ol","journal-title":"Leukemia"},{"issue":"24","key":"2019111703162915800_B36","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111703162915800_B37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111703162915800_B38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111703162915800_B39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703162915800_B40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111703162915800_B41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V128.22.1144.1144","article-title":"Primary IMiD refractory myeloma: results from 3894 patients treated in the phase III Myeloma XI study","volume":"128","author":"Pawlyn","year":"2016","journal-title":"Blood"},{"key":"2019111703162915800_B42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V128.22.241.241","article-title":"Final analysis of overall survival from the First Trial","volume":"128","author":"Facon","year":"2016","journal-title":"Blood"},{"issue":"10068","key":"2019111703162915800_B43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2019111703162915800_B44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","article-title":"Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM","volume":"127","author":"Mateos","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111703162915800_B45","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703162915800_B46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"34","key":"2019111703162915800_B47","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"2019111703162915800_B48","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111703162915800_B49","article-title":"Phase 3 study (CLARION) of carfilzomib, melphalan and prednisone (KMP) vs bortezomib, melphalan and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM)","author":"Facon"},{"issue":"1","key":"2019111703162915800_B50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111703162915800_B51","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.3324\/haematol.2014.110395","article-title":"Carfilzomib, lenalidomide and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma","volume":"99","author":"Dytfeld","year":"2014","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/498\/1250621\/hem00069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/498\/1250621\/hem00069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:48:48Z","timestamp":1574520528000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/498\/21148\/Management-of-multiple-myeloma-in-the-newly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.498","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}